Donepezil

Drug Profile

Donepezil

Alternative Names: Aricept; Aricept D; Aricept Dry Syrup; Aricept Evess; Aricept ODT; Aricept SR; Donepezil hydrochloride; Donepezil SR; E 2020; E 2022; Eranz

Latest Information Update: 16 Mar 2017

Price : $50

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; ICURE; Pfizer; Teikoku Pharma USA
  • Class Antidementias; Indans; Nootropics; Piperidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alzheimer's disease; Lewy body disease; Vascular dementia
  • Phase III Down syndrome
  • No development reported Attention deficit and disruptive behaviour disorders; Migraine
  • Discontinued Aphasia; Attention-deficit hyperactivity disorder; Dementia; Mild cognitive impairment

Most Recent Events

  • 09 Mar 2017 Eisai re-initiates enrolment in a phase III trial for Down syndrome (In children, In adolescents) in USA (EudraCT2016-004948-11)
  • 15 Apr 2016 Launched for Lewy body disease in Philippines (PO)
  • 14 Apr 2016 Registered for Lewy body disease in Philippines (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top